Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

  • Technology appraisal guidance
  • TA311
  • Published: 

History

Review proposal consultation

Multiple myeloma (induction therapy) -bortezomib: equality impact assessment -guidance review

Multiple myeloma - bortezomib (induction therapy): final appraisal determination

Multiple myeloma - bortezomib (induction therapy): appraisal consultation

Multiple myeloma - bortezomib (induction therapy): appendix D - response to consultee and commentator comments on the draft scope and provisional matrix

Multiple myeloma - bortezomib (induction therapy): final scope

Multiple myeloma - bortezomib (induction therapy): final matrix

Multiple myeloma - bortezomib (induction therapy): EIA scoping

Multiple myeloma - bortezomib (induction therapy): appendix B - draft scope for consultation (pre-referral) - November 2011

Multiple myeloma - bortezomib (induction therapy): Appendix C - provisional matrix (pre-referral) - November 2011